Stay updated on Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.
    Difference
    0.5%
    Check dated 2025-06-19T19:39:38.000Z thumbnail image
  3. Check
    18 days ago
    No Change Detected
  4. Check
    26 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-05T11:16:39.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The web page has been updated to reflect a modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, allowing API users to provide input. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    0.8%
    Check dated 2025-05-29T06:00:44.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The page has removed a citation regarding a clinical trial on pembrolizumab and axitinib for advanced renal cell carcinoma, which was previously included.
    Difference
    0.2%
    Check dated 2025-05-14T23:36:27.000Z thumbnail image
  7. Check
    61 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.
    Difference
    0.0%
    Check dated 2025-04-30T16:59:21.000Z thumbnail image
  8. Check
    76 days ago
    Change Detected
    Summary
    The page has undergone significant content changes, including the removal of detailed study information regarding the efficacy and safety of pembrolizumab in combination with axitinib for renal cell carcinoma, while adding a new registry identifier and revision number.
    Difference
    22%
    Check dated 2025-04-16T12:41:31.000Z thumbnail image

Stay in the know with updates to Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Axitinib vs Sunitinib in Renal Cell Carcinoma Clinical Trial page.